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Hydroxamic acid derivatives 
as HDAC1, HDAC6 and HDAC8 
inhibitors with antiproliferative 
activity in cancer cell lines
Yudibeth Sixto-López1, José Antonio Gómez-Vidal2, Nuria de pedro3, Martiniano Bello1, 
Martha Cecilia Rosales-Hernández4 & José correa-Basurto1 ✉
Histone deacetylases (HDACs) belong to a family of enzymes that remove acetyl groups from the 
ɛ-amino of histone and nonhistone proteins. Additionally, HDACs participate in the genesis and 
development of cancer diseases as promising therapeutic targets to treat cancer. Therefore, in this 
work, we designed and evaluated a set of hydroxamic acid derivatives that contain a hydrophobic 
moiety as antiproliferative HDAC inhibitors. For the chemical structure design, in silico tools (molecular 
docking, molecular dynamic (MD) simulations, ADME/Tox properties were used to target Zn2+ atoms 
and HDAC hydrophobic cavities. The most promising compounds were assayed in different cancer 
cell lines, including hepatocellular carcinoma (HepG2), pancreatic cancer (MIA PaCa-2), breast cancer 
(MCF-7 and HCC1954), renal cancer (RCC4-VHL and RCC4-VA) and neuroblastoma (SH-SY5Y). Molecular 
docking and MD simulations coupled to the MMGBSA approach showed that the target compounds 
have affinity for HDAC1, HDAC6 and HDAC8. Of all the compounds evaluated, YSL-109 showed the 
best activity against hepatocellular carcinoma (HepG2 cell line, IC50 = 3.39 µM), breast cancer (MCF-7 
cell line, IC50 = 3.41 µM; HCC1954 cell line, IC50 = 3.41 µM) and neuroblastoma (SH-SY5Y cell line, 
ic50 = 6.42 µM). In vitro inhibition assays of compound YSL-109 against the HDACs showed IC50 values of 
259.439 µM for HDAC1, 0.537 nM for HDAC6 and 2.24 µM for HDAC8.
Histone deacetylases (HDACs) are a family of enzymes able to remove acetyl groups from lysine residues in 
histones and nonhistone proteins, which includes chaperone proteins and transcription factors, among others1,2; 
the opposite effect is exerted by histone acetyltransferases (HATs)3. The family of HDACs include 18 members 
classified into four classes: class I (HDACs 1, 2, 3 and 8), class II subdivides into IIa (HDACs 4, 5, 7 and 9) and IIb 
(HDACs 6 and 10) and class IV (HDAC11), all of which are Zn2+ dependent, whereas class III, also called sirtuins, 
are NAD+-dependent enzymes2.
Due to the biological importance of HDACs, their inhibition has emerged as an important strategy to treat 
several diseases, including cancer4–6, neurodegenerative diseases7,8, cardiac diseases9, immune diseases10, inflam-
matory diseases11, and other disorders12,13.
It has been described that HDAC inhibition produces cell cycle arrest, the inhibition of tumor angiogenesis, 
differentiation of some transformed cell lines14 and/or apoptosis in tumor cells4,5,15, showing particular impor-
tance as a pharmacological target for cancer treatment. Currently on the market, there are five HDAC-related 
compounds approved for cancer treatment: vorinostat (suberoylanilide hydroxamic acid, SAHA), romidepsin, 
chidamide and Belinostat for T-cell lymphoma and panobinostat for the treatment of myeloma16,17.
HDAC1, HDAC6 and HDAC8 are isoforms belonging to different HDAC classes, and localize in different 
locations within the cell2. HDAC1 and HDAC8 are mainly localized in the nucleus2 while HDAC6 is mainly 
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localized in the cytoplasm18. These HDACs have been linked to cancer progression and development19 and are 
also related to neurodegenerative diseases7,18,20,21. These differences suggest the importance in the development of 
isoform-selective HDAC inhibitors (HDACi) to enhance drug efficacy and decrease side effects22,23. HDAC inhib-
itors have common structural features that allow them to interact with HDAC enzymes by means of noncovalent 
interactions. The general pharmacophore of HDACi include (a) a zinc chelating group, (b) a linker group, which 
is generally hydrophobic to fit the catalytic site channel, and (c) a capping group, which interacts with the hydro-
phobic surface region and is the main factor responsible for isoform selectivity24–26. Therefore, structural insights 
into the binding differences among HDAC isoforms that permits the design of new HDACi with improved affin-
ity and selectivity need to be explored. In this sense, several structural studies have been performed revealing 
particular differences among HDAC isoforms. In the case of HDAC8, experimental and theoretical studies have 
revealed the presence of several possible binding sites, including the catalytic site (CS)27,28, an alternate site of 
entry adjacent to the catalytic site that reaches the CS and consists of a 14 Å so-called tunnel adjacent to the 
catalytic site pocket (ACSP)27,29, and this a 14 Å tunnel26,30 and the acetyl-release channel (HSAC)31,32 are mostly 
characterized by their hydrophobic nature. In addition, selective HDAC1 inhibitors can be obtained by exploit-
ing the foot pocket (14 Å channel), which is observed in class I HDACs but not in class IIa33, which is important 
for the correct catalytic activity of the enzyme34. On the other hand, molecular modeling studies indicate that 
DD2-HDAC6 (the catalytic domain 2 of HDAC6) has structural differences in the cap region, which is more 
flexible in comparison to the class I isoforms22,35–37. It also possesses a tunnel that is wider and more shallow7,37, 
structural data supported by X-ray diffraction studies placed at Protein Data Base (PDB): 5EDU (Human), 5EEF, 
5EEI, 5EEK, 5EEM, 5EEN, 5EF7, 5EF8, 5EF8, 5EFG 5EFH, 5EFJ, 5EFK and 5EFN (Danio), and therefore, it has 
been suggested that the use of bulky and aromatic moieties would increase the selectivity for HDAC618,26.
Therefore, we designed a new series of compounds that contain two pharmacophore moieties (hydroxamic 
and aromatic) to target HDAC1, HDAC6 and HDAC8 to be assayed as antiproliferative compounds on cancer 
cell lines (HepG2, MCF-7, SH-SY5Y, MIA PaCa-2, HCC1954, RCC4-VA, RCC4-VHL), exploring the binding 
pose using molecular docking and molecular dynamics (MD) simulations on HDAC1, HDAC6 and HDAC8 and 
further validation with in vitro assays.
Results and Discussion
HDACs deacetylate histone and nonhistone proteins2, and an imbalance in their function or expression is 
involved in diverse disease states, such as cancer4–6 and neurodegenerative diseases7, among others9–12. HDACs 
are one of the most promising therapeutic targets for the treatment of cancer and have been widely stud-
ied15,19,20,38,39. First, a set of 7 hydroxamic acid derivatives were developed (GH38, GH18, GH27, FH38, FH18, 
FH27 and FH37, Scheme 1), and FH27 was identified as a lead compound, through cytotoxic evaluation on 
HepG2, MCF-7 and MIA PaCa-2, where 50 µM of the above compound were tested in order to obtain the % of 
Scheme 1. First generation of hydroxamic acid derivatives, including the lead compound FH27.
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inhibition in the cell viability (Table 1), besides from a previous work, it was found by blind molecular docking 
that FH27 did not reached the catalytic site of HDAC1 and HDAC8, reaching HDAC6 over the other two iso-
forms (paper not published yet) taken into account the in silico approach and in cytotoxicity, this compound was 
used to develop a second series of compounds to target HDAC1, 6 and 8.
Lead compound optimization. Molecular modeling studies showed that FH27 reaches the catalytic site 
and is coordinated with Zn in bidentate way (2.887 and 2.677 Å) (Fig. 1B), and interacts with residues belong-
ing to the internal cavity, leaving free the cap region of DD2-HDAC6; thus, there were opportunities to include 
voluminous groups such as the bulky naphthyl, electron donating (-OH) or electron withdrawing (–F, –I, –NO2) 
Compound
HepG2 MCF-7 MIA PaCa-2
IC50
% Inhibition at 
50 µM IC50
% Inhibition at 
50 µM IC50
% Inhibition at 
50 µM
GH38 >50 1.01 >50 16.10 >50 0.18
GH18 >50 3.08 >50 17.22 >50 4.44
GH27 >50 1.38 >50 40.40 >50 10.72
FH38 >50 14.07 >50 20.98 >50 0.43
FH18 >50 5.52 >50 41.24 >50 0.05
FH27 >50 35.36 >50 37.59 >50 2.82
FH37 >50 48.56 >50 49.11 >50 7.47
Table 1. Results of the cytotoxic evaluation in HepG2, MCF-7 and MIA PaCa-2 cell lines as shown as the % 
inhibition at 50 µM.
Figure 1. Binding mode of studied compounds retrieved from focused molecular docking. (A) HDAC1, (B) 
HDAC6 and (C) HDAC8. From left panel HDAC is in white ribbon representation, FH27, YSL99, YSL106, 
YSL112, YSL116, YSL121, YSL125 and YSL129 are depicted as wire, while YSL109 is depicted as cyan ball and 
stick, in the middle panel a zoom on the YSL109 and residues with which it interacts are depicted, YSL109 is 
depicted as cyan ball and stick, while interacting residues as green sticks; and finally in the right panel a surface 
representation of the catalytic tunnel is depicted in gray, YSL109 is depicted in cyan, while FH27 is depicted in 
yellow ball and stick, Zn is depicted as gray sphere. Figure built with Pymol and UCSF Chimera softwares.
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groups in the cap region composed of a phenyl group7,35,36,40. Additionally, with the aim of exploring whether 
the stereochemical properties affect the biological effects, the R form of the lead compound (YSL-106) was syn-
thesized. As a result, eight compounds were synthesized (Table 2 following a solid-phase synthesis protocol 
(Scheme 2).
Molecular docking. Molecular docking procedures were used to generate the starting coordinates of the 
HDAC ligands to perform the MD simulation studies. The lead compound and derivatives showed a common 
binding mode within HDAC1 (Fig. 1A). The hydroxamic group of the ligands reached the bottom of the hydro-
phobic tunnel and were coordinated with the Zn2+ through hydroxamic group, except YS-106, that is slightly dis-
placed toward the internal cavity of HDAC1 and interacted with Zn2+ through the oxygen of the amide function. 
The phenyl moiety of the compounds is inserted into the 14 Å tunnel and exposed its aliphatic portion toward the 
surface region. YSL-109 and YSL-112 fit better into the 14 Å tunnel because their naphthyl portion was accommo-
dated better along the tunnel and, at the same time, the hydroxyl group of the hydroxamic acid moiety interacted 
with Zn2+ (Fig. 1A).
All the tested ligands recognize and make similar binding mode on HDAC6 and were coordinated with 
Zn2+(Fig. 1B), except for YSL-121 (See Supplementary information, Figs. S1 and S2). All compounds inserted 
the naphthyl portion toward the 14 Å, except YSL-112; instead, it occupied the hydrophobic tunnel together 
with the linker (aromatic and aliphatic) region. YSL-121 was accommodated into the hydrophobic tunnel in a 
Second Generation IC50 (µM)
Name R1 HepG2 MIA PaCa-2 MCF-7 HCC1954 RCC4-VA RCC4-VHL SH-SY5Y
YSL-99 30.88 >50 8.96 42.90 >50 >50 36.19
YSL-106 11.55 21.55 4.94 26.10 12.92 21.10 18.91
YSL-109 3.39 >50 3.41 3.77 24.87 32.69 6.42
YSL-112 10.85 >50 7.27 7.62 31.87 46.50 21.44
YSL-116 17.98 >50 27.88 17.97 38.87 44.17 19.62
YSL-121 41.14 >50 >50 8.49 >50 >50 1.41
YSL-125 15.69 42.52 16.64 14.77 10.46 8.02 6.50
YSL-129 >50 >50 >50 >50 >50 >50 >50
Table 2. Antiproliferative activities of the second series of compounds against different cancer cell lines.
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reverse manner, where the aliphatic chain was oriented toward the Zn2+ or the hydrophobic portion was placed 
in the surface region (See Supplementary information, Fig. S2). Finally, the remaining ligands repeated the same 
binding mode as that observed for the other isoforms (hydroxamic acid toward the Zn2+ atom), except YSL-106, 
which did not interact with Zn2+ even when it was placed at the end of the catalytic tunnel (Fig. 1B). Trichostatin 
A (TSA), which has an aromatic and a hydroxamic groups reproduces the typical binding mode reported for 
HDACs28,41,42.
While for HDAC8, all compound except YSL-106, share a similar binding mode, since they were coordinated 
with Zn2+ in a monodentate way through the hydroxyl portion of the hydroxamic group, while the phenyl and 
naphthyl rings were inserted into the 14 Å tunnel and the aliphatic chain protrude to the outer of the catalytic 
tunnel, in case of YSL-106, the only difference regarding the other molecules was that it did not coordinate the 
hydroxamic portion with Zn2+ (Fig. 1C) (Supplementary information, Figs. S1 and S2).
Antiproliferative activity. Furthermore, we evaluated the antiproliferative effect of the synthesized second 
series of compounds in different cancer cell lines. As shown in Table 2, addition of the hydroxyl group at the para 
position of YSL-99 did not show a significant effect on cytotoxicity; however, it showed cytotoxicity effects against 
the MCF-7 breast cancer cell line.
The R isomer of the lead compound (YSL-106) was synthesized to evaluate the stereoselectivity of 
HDAC inhibitors on biological activity since there have been previous reports where this influence has been 
described43,44. YSL-106 shows an enhanced cytotoxic effect compared to FH27. Further, studies need to be per-
formed to evaluate the in vitro isoform selectivity of this compound to explain our biological findings, but it 
seems that YSL-106 shows improved biological activity, which might be at the expense of isoform selectivity as 
the MD simulations point out (see further details).
The addition of bulkier substituents was studied by adding α- and β-naphthyl residues, obtaining YSL-109 
and YSL-112, respectively. With regard to their cytotoxic activity, YSL-109 in most cases showed better activity 
than YSL-112.
YSL-129 did not show biological activity, which could be due to the elimination of the β-carbon, suggesting 
that the presence of the β-carbon is important for the biological activity of these compounds.
Fluorine and iodine were added to YSL-116 and YSL-121, which are electron donating groups; moreover, 
the electron withdrawing nitro group was added to YSL-125. The inclusion of fluorine in the structure of YSL-
116 detrimentally affected the antiproliferative effect, but this compound was still superior to FH27 (5.59 µM vs 
13.70 µM ± 4.10). In contrast, YSL-121 showed more limited antiproliferative effects because these effects were 
only observed in hepatoma HepG2 cells (41.14 µM), breast cancer HCC1954 cells (8.49 µM), and neuroblastoma 
SH-SY5Y cells (1.41 µM), with the best activity being observed in the SH-SY5Y cells.
YSL-125 showed a better cytotoxic effect in the renal carcinoma RCC4-VA and RCC4-VHL cell lines, of which 
RCC4-VA shows overexpression of hypoxia-inducible-factor (HIF), which is a gene involved in the regulation 
of the expression of a large number of target genes involved in tumor progression45, including those regulated 
by oxygen46. On the other hand, RCC4-VHL shows a normal level of expression of HIF, which corresponds to 
the wild type cell line46. The cytotoxic effect of YSL-125 was similar in both cell lines; therefore, we can broadly 
suggest that this compound may have HDAC6 inhibitory activity based on the structural similarity with YSL-
109 since HDAC6 in numerous studies has been shown to be involved in the degradation of HIF47,48 through a 
VHL-independent way49.
Scheme 2. Solid-phase synthesis of hydroxamic acid derivatives.
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Molecular dynamics simulations. Once the biological activities of the compounds were determined, MD 
simulations of the complexes (compound-HDAC) of the nine compounds with biological activity were carried 
out to predict the affinity for HDAC1, HDAC6 and HDAC8. HDAC1 shares sequence homology with HDAC2 
and HDAC3 and is generally inhibited with almost the same strength by inhibitors50, and so in this way, the MD 
simulations may encompass or have a notion about the possible behavior of the compounds with regard to class 
I HDACs.
First, the starting coordinates of the compounds were obtained for molecular docking using the improved 
forcefield Autodock4zn51. Since the criteria of selection was to take the coordinates of the ligand coordinated 
with the Zn2+ by its hydroxamic moiety, this objective was achieved by reducing the size of the grid box in all 
cases at the expense of increasing the value of the binding free of energy (Table S1), even allowing this value to 
become positive, such as was the case for FH27 and the compounds from the second series in complex with 
HDAC6, except for TSA (−6.11 kcal/mol). In the case of HDAC1, the binding free energies were thermodynam-
ically favorable in the range of −40 to −11 kcal/mol. For HDAC8, the binding free energy values ranged from 
−32 to −6 kcal/mol, except for YSL-109 and YSL-112, which are naphthyl derivatives that showed positive values 
(Supplementary information, Table S1). The positive values obtained might indicate that this is not the most 
favorable conformer of the ligand; thus, favorable interactions were not established. However, with the use of this 
conformation as the starting structure for MD simulations, it was indicated that these conformations are stable 
if this binding mode was maintained, or they were deemed not stable if they changed their position or broke the 
complex during the MD simulation time.
To determine the average deviations in the atomic positions and stability under the MD simulations, the 
RMSD values of the trajectories of the protein-ligand complexes were calculated (Supplementary information, 
Table S2). The RMSD showed that the HDAC1-ligand complex reached a faster constant structural behavior 
(Fig. 2A) than the protein-ligand complexes formed with HDAC6 (Fig. 2B) and HDAC8 (Fig. 2C). HDAC1 
showed mean RMSD values between 1.24 and 1.87 Å, while the RMSD values for HDAC6 were between 1.54 
and 2.45 Å and those for the HDAC8 complexes were between 2.45 and 5.38 Å (Table S2). The Rg values of the 
complexes in HDAC1 ranged from 20.194 Å ± 0.037 Å to 20.388 Å ± 0.055 Å (Fig. 3A), for HDAC6, this range was 
from 19.506 Å ± 0.050 Å to 20.0494 Å ± 0.066 Å (Fig. 3B), and for HDAC8, this range was from 20.352 Å ± 0.093 Å 
to 21.117 Å ± 0.146 Å (Fig. 3C), demonstrating that the three systems have a similar degree of compactness 
(Supplementary information, Table S2). Based on this analysis, the first 10 ns were excluded from the structural 
and energetic analyses.
The RMSF analysis for the HDAC1 complexes showed that YSL-121 and YSL-106 displayed higher fluctua-
tions (>3 Å) in the E203-R212 region, while YSL-109 decreased the RMSF below 1 Å. Moreover, the other ligands 
oscillated between 2.6 Å−1 Å. This E203-R212 region is part of the loop surrounding the cap region that leads 
to the catalytic site. In apo-HDAC1, this region was also observed with higher RMSF values. The target ligands 
Figure 2. Root mean square deviations (RMSDs) of the ligand-HDAC complexes. (A) RMSDs of HDAC1-
ligand, (B) RMSDs of HDAC6-ligand, and (C) RMSDs of HDAC8-ligand. Figure built with GraphPad software.
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were able to reduce the RMSF in comparison to the apo-HDAC1 model52. Other regions with relatively higher 
fluctuations are the G27-P29, P81-D99, and G268-C273 regions, whose structural behaviors were also found in 
a previous work of ligands with inhibitory activity against HDAC152. However, the E337-F341 and S346-E361 
regions also displayed high fluctuations, a structural feature that had not been reported for HDAC1-ligand com-
plexes (Fig. 4A). These E337-F341 and S346-E361 regions are interconnected and form part of a long loop region 
away from the catalytic tunnel (Supplementary information, Fig. S3), revealing that loops not only near to the 
catalytic tunnel undergo structural modifications to accommodate ligands into the catalytic site.
In the HDAC6 complexes, the fluctuations of catalytic domain 2 (G482-G800) were less than that observed 
(~4 Å) in a previous study of apo-HDAC6 domain 2. However, higher fluctuations did exist in the D497-V503 
region (<2.8 Å) and M554-C572 region (<3.2 Å), which is minor portion of apo-HDAC6 domain 2 (<4 Å).37. 
There are two regions, D747-V754 and T807-L817 (Fig. 4B), that display the highest fluctuations (<4.7 Å and 
<4.8 Å, respectively), of which D747-V754 belongs to a loop region adjacent to the catalytic site, and T807-L817 
is also part of a loop, but this loop is further from the catalytic site; therefore, the same phenomenon that was 
described for HDAC1 was also observed for HDAC6 domain 2 (Fig. 3B) (Supplementary information, Fig. S4).
In the case of the HDAC8-ligand complexes (Fig. 3C), the structural fluctuations were higher from M1 to 
Q12, which is part of a missing loop in crystal structures since it has substantial motility and high conformational 
flexibility (higher than 5 Å) that was reproduced by our MD simulations. This behavior was also found for this 
region in apo-HDAC8 in a previous work32. On the other hand, the residues belonging to loop 2 (E85-D102), loop 
3 (H142-Y154), loop 5 (K204-G212), loop 7 (G265-C275) and loop 9 (K325-R361) displayed higher fluctuations 
in comparison to the other regions of the protein (Fig. 4C). YSL-112 showed the highest RMSF for loop 2 (>4 Å), 
and the other ligands (YSL-99, YSL-106, YSL-109, YSL-112, YSL-116, YSL-121 and YSL-125) showed values in the 
range of 2.5 Å to 3.4 Å. In loop 3, this value ranged from 0.6 Å to 2.83 Å, and higher values were observed for YSL-
125, YSL-121 and YSL-106 (1.3–2.83 Å); the other ligands showed lower values (<1.3 Å). In loop 5, compounds 
YSL-99, YSL-109, YSL-112, YSL-116 and YSL-121 showed RMSF values from 3.6 Å to 5.4 Å, and YSL-106 and 
YSL-125 displayed values from 1.6 Å to 2.2 Å. In loop 7, only FH27, YSL-106, YSL1–09, YSL-116, YSL-121 and 
YS-L125 showed higher fluctuations (0.90–3.57 Å), with the highest fluctuation observed for YSL-106 (>1.5 Å). 
In contrast, in loop 9, all the complexes showed fluctuations higher than 1.0 Å in this region and all were higher 
than 1.5 Å except for YSL-106. Thus, these regions (L2, L3, L5 and L7) represent a zone of higher fluctuation in 
holo-HDAC8, and all except L9 are adjacent to the catalytic site; of which L9 is far from the catalytic site but is 
affected by the ligand coupling process. L2, L5, L7 and L9 showed higher fluctuations in Apo-HDAC8 but L3 did 
not, which, in this work, only some ligands were able to produce increased fluctuations in this region32. Hence, 
the residues that belong to loops 2 and 5 participated in the accommodation of ligands into the catalytic tunnel, 
which is in line with previous reports29,32.
Further, MD simulations of the carboxylic acid derivatives (the target compounds with carboxylic acid instead 
of hydroxamic acid) in complex with HDAC1, HDAC6 and HDAC8 were also evaluated to test whether the 
Figure 3. Radius of gyration (Rg) of the ligand-HDAC complexes. (A) Rg of HDAC1-ligand, (B) Rg of 
HDAC6-ligand, and (C) Rg of HDAC8-ligand. Figure built with GraphPad software.
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hydroxamic or carboxylic groups are the zinc binding group (ZBG) that guide the binding of the hydroxamic 
acids synthetized in this work. However, it was found that most of the carboxylic acids were not able of reaching 
the Zn 2+ atom through the carboxylic groups, in spite carboxylic acid is a demonstrated ZBG53, instead they 
were inserted by the butyl chain into the catalytic tunnel locating away from Zn 2+ (>4.5 Å), being anchored at 
the entrance of the catalytic tunnel by the aromatic alkyl portion (Supplementary information, Fig. S5). So, based 
on these findings we hypothesized that hydroxamic group do not govern the recognition of some of these mole-
cules, and the aromatic portion might be the responsible for the binding.
Free energy calculations. Furthermore, the free energies of binding (FEBs) among the ligands and HDACs 
were estimated using the MMGBSA approach. In Fig. 5, the free energies of the HDAC-ligand complexes are 
shown. FH27 and YSL-121 showed higher affinity for HDAC6 in comparison to that observed for HDAC1 and 
HDAC8, while YSL-99, YSL-106, YSL-109, YSL-112 and YSL-116 showed a greater affinity for HDAC1 in com-
parison to HDAC6 and HDAC8, and only YSL-125 showed favorable affinity for HDAC8. Interestingly, the 
Figure 4. Root mean square fluctuations (RMSFs) of ligand-HDAC complexes. (A) RMSFs of HDAC1-ligand, 
(B) RMSFs of HDAC6-ligand, and (C) RMSFs of HDAC8-ligand. Regions with higher fluctuations were 
enlarged and depicted in the upper part or on the side of the corresponding region. Figure built with GraphPad 
software.
Figure 5. Free energy of binding of the HDAC-ligand complexes calculated by the MMGBSA method. Figure 
built with GraphPad software.
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compounds with a higher affinity for HDAC1 were those with better cytotoxic activity against the cancer cell lines 
evaluated (Table 2).
Table 3 shows the FEBs, the molecular mechanics components, and polar (ΔEelec + ΔGGB) and non-
polar (ΔEvdw + ΔGSA) solvation energy terms. In HDAC1 complexes, the nonpolar contributions 
(ΔEvdw + ΔGSA) dominate in all HDAC1-ligand complexes, except for YS-L121, in which the non-favorable 
polar (ΔEelec + ΔGGB) contributions predominate, rendering unfavorable complex interactions. Similar behav-
ior was observed for the complexes FH27-HDAC1 and YSL-125-HDAC1, where nonpolar contributions screened 
this effect yielding FEB values of −1.61 ad −2.65 kcal/mol, respectively. In the YSL-99, YSL-106, YSL-109 and 
YSL-116 complexes with HDAC1, favorable contributions from the terms ΔEvdw, ΔESA, ΔEelec were detected; 
however, the largest unfavorable ΔGGB and stronger polar solvation energy contributions were also observed, 
which was screened by the other terms. However, for YSL-112-HDAC1, a fine balance between the polar and 
nonpolar contributions was observed, giving a favorable FEB, but in general, hydrophobic interactions guided 
the binding. The affinity of the inhibitors for HDAC1 was as follows: YSL-99> YSL-109> YSL-112> YSL-106> 
YSL-116> TSA > YSL-125 > FH27 > YSL-121.
In the HDAC6 complexes, nonpolar contributions also dominated the FEB values, despite the higher unfa-
vorable contribution from ΔGGB, which was screened by the nonpolar contribution ΔGelec. For YSL-125, non-
polar contributions predominated, rendering an unfavorable FEB for the complex, and with FH27, a balance 
between the contributions was observed, giving a favorable FEB. The affinity of the inhibitors for HDAC6 was as 
follows: YSL-99> YSL-121> TSA > FH27 > YSL-109> YSL-112> YSL-106> YSL-116> YSL-125.
In HDAC8 complexes, more variability was observed since fewer compounds showed favorable FEB values for 
this isoform (only TSA, YSL-106, YSL-112 and YSL-125), in which cases the nonpolar contributions dominated 
the FEB even though the ΔGGB values were higher as screened by the favorable nonpolar and ΔGelec contri-
butions. In the other complexes, the polar contributions were higher than the nonpolar contributions, yielding 
an unfavorable FEB. The affinity of the inhibitors for HDAC8 was as follows: YSL-125 > TSA > YSL-106> YSL-
112> YSL-116> YSL-121 > FH27 > YSL-99. Overall, the favorable interactions established between the ligand 
and the protein are mainly mediated by hydrophobic contacts.
HDAC1 FEBb ΔEvdwc ΔEelecd ΔGGBe ΔGSAf Polarg Nonpolarh
FH27 −1.6153 −48.572 11.960 41.2212 −6.224 53.1812 −54.796
YSL-99 −23.632 −37.568 −12.969 32.1939 −5.2883 19.2249 −42.8563
YSL-106 −15.21 −53.225 −3.1995 47.353 −6.1385 44.1535 −59.3635
YSL-109 −21.29 −55.998 −10.796 52.5679 −7.0636 41.7719 −63.0616
YSL-112 −17.862 −58.685 7.8076 40.0951 −7.0799 47.9027 −65.7649
YSL-116 −14.147 −48.161 −1.5793 41.8915 −6.2982 40.3122 −54.4592
YSL-121 2.5817 −51.013 26.555 32.9591 −5.9194 59.5141 −56.9324
YSL-125 −2.6567 −49.37 35.3306 17.7303 −6.3474 53.0609 −55.7174
TSA −6.7754 −43.166 17.2393 24.9624 −5.8115 42.2017 −48.9775
HDAC6 FEBb ΔEvdwc ΔEelecd ΔGGBe ΔGSAf Polarg Nonpolarh
FH27 −11.114 −27.296 2.3508 17.7179 −3.8874 20.0687 −31.1834
YSL-99 −21.391 −36.127 −34.073 53.8762 −5.0668 19.8032 −41.1938
YSL-106 −2.1265 −39.457 −3.0172 49.3126 −5.2188 46.2954 −44.6758
YSL-109 −10.488 −41.373 −8.3282 44.7596 −5.5466 36.4314 −46.9196
YSL-112 0.3457 −37.519 −7.9263 50.4008 −4.6101 42.4745 −42.1291
YSL-116 4.1838 −34.8674 −20.228 65.0665 −5.7877 44.8385 −40.6551
YSL-121 −17.977 −31.547 −63.657 81.8689 −4.6418 18.2119 −36.1888
YSL-125 15.2455 −45.498 32.7453 34.1884 −6.1907 66.9337 −51.6887
TSA −13.825 −28.234 −32.349 50.5371 −3.7793 18.1881 −32.0133
HDAC8 FEBb ΔEvdwc ΔEelecd ΔGGBe ΔGSAf Polarg Nonpolarh
FH27 10.5606 −35.149 10.5555 39.8472 −4.6935 50.4027 −39.8425
YSL-99 12.9324 −28.784 −0.3995 46.3877 −4.2718 45.9882 −33.0558
YSL-106 −11.346 −34.388 −33.614 61.6079 −4.9523 27.9939 −39.3403
YSL-109 16.5194 −37.752 19.7418 39.5541 −5.0239 59.2959 −42.7759
YSL-112 −5.0453 −44.672 −4.3563 50.0299 −6.0464 45.6736 −50.7184
YSL-116 0.0635 −42.224 15.1292 32.5402 −5.3817 47.6694 −47.6057
YSL-121 6.3736 −35.485 −13.08 59.2932 −4.3547 46.2132 −39.8397
YSL-125 −26.383 −40.522 −80.572 99.3852 −4.674 18.8132 −45.196
TSA −15.012 −25.169 −39.216 53.3842 −4.0107 14.1682 −29.1797
Table 3. Free energy of binding of the compounds with antiproliferative effects against HDAC1, HDAC6 
and HDAC8 obtained using the MMGBSA methoda. aAll energies are in kcal/mol, bFEB = Free energy of 
binding, cΔEvdw = Contribution to the FEB from the van der Waals energy, dΔEelec = Contribution to 
the FEB from the electrostatic energy, eΔGGB = Contribution to the FEB from the polar solvation energy, 
fΔGSA = Contribution to the FEB from the solvent accessible surface energy
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HDAC activity. The in silico studies (binding pose) and antiproliferative assays guided us to select the best 
HDAC inhibitory activity of YSL-109 as evaluated against HDAC1, HDAC6 and HDAC8. YSL-109 inhibited 
HDAC6 in a highly selective manner (0.537 nM) compared with HDAC8 and HDAC1, and showed 4000-fold 
selectivity (Table 4). Thus, YSL-109 is a highly selective HDAC6 inhibitor that is more potent than TSA (Fig. 6) or 
the other inhibitors that have been reported [7].
Conclusion
A set of hydroxamic acid derivatives were designed, submitted to a virtual screening protocol evaluating the 
ADME/Tox properties in combination with MD simulations and molecular docking studies for HDAC1, HDAC6 
and HDAC8, and validated with in vitro assays on pure enzymes. Then, the most promising compounds were 
assayed in a panel of cancer cell lines, which identified that YSL-109 showed promising activity against hepatocel-
lular carcinoma (HepG2 cell line, IC50 = 3.39 µM), breast cancer (MCF-7 cell line, IC50 = 3.41 µM; HCC1954 cell 
line, IC50 = 3.41 µM) and neuroblastoma (SH-SY5Y cell line, IC50 = 6.42 µM). In addition, MD simulation studies 
were not able to reproduce the experimental selectivity. Through this screening, we obtained a highly selective 
HDAC6 inhibitor with an IC50 of 0.537 nM.
Experimental section
Computational methodology. Molecular modeling. The crystal structure of HDAC1 was obtained from 
the Protein Data Bank (PDB ID: 4BKX). Water, sulfate and acetate molecules were stripped from the system. 
Structural potassium ions were left due to their importance in the catalytic activity as suggested by their presence 
and conserved position among HDAC isoforms33. The in silico studies revealed that these ions play a structural 
role since their absence masks the motility of the loops adjacent to the catalytic sites52. For HDAC6, catalytic 
domain 2 (DD2-HDAC6) was retrieved from a previous work37. The structure of HDAC8 was taken from the 
PDB (PDB entry 3F07), and the missing loop region (M1-Q12) was modeled using Modeller54 as described in 
a previous work32. Between isoforms, the amino acid sequence identity and similarity for HDAC1 and DD2-
HDAC6 are 24.6% and 40.7%, for HDAC1 and HDAC8 are 40.1% and 61.5%, and for HDAC8 and DD2-HDAC6 
are 24.9% and 40.9%, respectively55.
Molecular docking. The compounds were submitted for molecular docking using Autodock4Zn, an improved 
force field of AutoDock for the docking of zinc metalloproteins51. Ligands were prepared with AutoDock Tools 
IC50 (nM)
HDAC1 HDAC6 HDAC8
YSL-109 259439.68 0.537 2242.72
TSA 7.61 9.72 98.83
Table 4. IC50 values of YSL−109 against HDACs.
Figure 6. Evaluation of the enzymatic activity of TSA against (A) HDAC1, (B) HDAC6 and (C) HDAC8 
and YSL-109 against (D) HDAC1, (E) HDAC6 and (F) HDAC8 obtained from two distinct experiments in 
duplicate. *P < 0.05. Figure built with GraphPad software.
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1.5.756. Focused docking was performed, and the grid box was centered on Zn2+ with dimensions of 44 × 30 × 
30 Å to 48 × 30 × 30 Å and a grid space of 0.375 Å3. For scoring sampling, a Lamarckian-Genetic Algorithm 
with a randomized initial population of 100 individuals and a maximum number of energy evaluations of 1 × 
107 with 200 runs were performed. A cluster analysis was performed. The cluster in which hydroxamic acid was 
coordinated with the Zn2+ atom was used as the starting conformation for performing the ligand-protein MD 
simulations.
Molecular dynamics simulations. MD simulations of the ligand-receptor proteins were 10 ns long and carried 
out with the AMBER 12 package57. Ligand parameters were generated with the antechamber module, based on 
the generalized AMBER force field (GAFF)58 and the AM1-BCC atomic charges were calculated with the ante-
chamber module. To explore the ligand-HDAC6 and ligand-HDAC8 complexes, the force field ff99SB59 was used, 
and for the ligand-HDAC1 complex, the force field ff12SB60 was used due to a previous study performed in our 
group in which the role of potassium ions in the structure of HDAC1 was suggested52. For carboxylic acid deriv-
atives, the forcefield ff14SB was used. The systems were neutralized with Na+ ions, centered into a rectangular 
12 Å box and solvated with a water TIP3P model61. The tleap module was used to prepare the protein and mini-
mized with a sander module. The MD simulations were run with pmemd.cuda executable57 using graphical units 
processors62,63. Zn2+ was replaced by a tetrahedron-shaped zinc divalent cation conformed by 4 cationic dummy 
atoms around the central zinc64,65. Energy minimization was carried out through 1000 steps of steepest descent 
followed by 1000 steps of conjugate gradients and equilibrated through 100 picoseconds (ps) of heating and 100 ps 
of density equilibration with weak restraints on the complex followed by 300 ps of constant pressure equilibration 
at 300 K. The SHAKE algorithm66 was applied to the hydrogen atoms with a step time of 2 femtoseconds and a 
Langevin thermostat for temperature control. 10 ns and 25 ns of MD simulations for hydroxamic acid and carbox-
ylic acid, respectively, were carried out without position restraints under periodic boundary conditions using the 
NPT ensemble at 300 K. The electrostatic term was described through the particle mesh Ewald method67, and for 
van der Waals interactions, a 10.0 Å cutoff was used. In the MD simulations, the SHAKE algorithm was used, and 
the time step was set to 2.0 fs. The temperature and pressure were maintained with the weak coupling algorithm68 
with coupling constants τT and τp of 1.0 and 0.2 ps, respectively (300 K, 1 atm). Coordinates were saved every 
1 ps. To analyze the trajectories, the ptraj module of AMBER 1257 was used. Translation and rotational move-
ments were removed from the protein before the calculation of the root mean square deviation (RMSD). Root 
means square fluctuations (RMSFs) and the radius of gyration (Rg) were used to determine when the trajectories 
reached equilibrium.
Energetic analysis. Once the MD simulations reached equilibrium, the binding free energy was calculated 
using the MMGBSA method and the single trajectory approach69, employing MMPbSA.py script70, in a salt con-
centration of 0.1 M and a Born implicit solvent model of 2 (igb = 2)71. Water molecules and metal ions were 
stripped from the system prior to performing the calculation, which was performed at intervals of 10 ps. With 
the MMGBSA method, the free energy of binding (ΔGbind) of the complex in solution was estimated to be72 as 
follows:
Δ = Δ + Δ Δ–G E G T S (1)bind MM solv
Δ = Δ + Δ + ΔE E E E (2)MM internal electrostatic vdw
Δ = Δ + ΔG G G (3)sol GB SA
where ΔEMM is the change in gas phase MM energy and includes ΔEinternal (bond, torsional angle and dihedral 
energies), ΔEelectrostatic and van der Waals energies ΔEvdw. Moreover, ΔGsolv is the sum of the electrostatic solvation 
energy (polar contribution, ΔEGB) and nonelectrostatic solvation component (nonpolar contributions, ΔGSA). 
The polar contribution was calculated using the GB model, while the nonpolar energy was estimated by the sol-
vent accessible surface (SASA). The conformational entropy change -TΔS in the present study was not calculated; 
therefore, we present the effective binding free energy69.
Chemistry. All compounds were routinely checked by TLC and 1H NMR. TLC was performed on alumi-
num plates coated with silica gel (TLC Plate Silica Gel 60 F254), and the spots were visualized with UV light, 
FeCl3 solution, iodine or vanillin, depending on the characteristics of each compound. 1H NMR was performed 
using a 300 MHz Varian Inova spectrometer, and 13C NMR was performed using a Varian Direct Drive (75 MHz) 
spectrometer. The high-resolution electrospray ionization time-of-flight mass spectrometry (HRMS-ESI-TOF) 
technique was used to obtain a mass spectrum of high resolution, which was performed using a time of flight ana-
lyzer (LCT Premier, Waters) on an Agilent 6545 Q-TOF LC/MS. The chemical purity was determined by HPLC 
employing an Agilent 1200 Infinity Series system.
Spectra of low resolution were obtained using a liquid chromatography-mass spectrometry technique with an 
ESI and a single quadrupole mass detector (Agilent 6110). Liquid chromatography (LC) was performed through 
automatic injection into the HPLC (binary pump) with a C-18 reversed-phase column (150 × 4.6 mm, Zorvax). 
The mass analyzer detected in positive ion mode. The solvents used for LC/MS were buffered with 0.1% formic 
acid. The chromatographic retention time was converted to minutes and seconds in the format 60.60 min.
In the HPLC, two methods were used to evaluate the purity of the compound synthesized:
Method A: Chromatographic parameters: the flow rate was set to 0.8 mL/min, initially isocratic for 2 min (ace-
tonitrile:water 40:60; A), final isocratic at 0 min (acetonitrile; B), gradient from A to B over 10 min.
1 2Scientific RepoRtS |        (2020) 10:10462  | https://doi.org/10.1038/s41598-020-67112-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Method B: Chromatographic parameters: the flow rate was set to 0.8 mL/min, initially isocratic for 2 min (ace-
tonitrile:water 20:80; A), a final isocratic at 0 min (acetonitrile; B), gradient from A to B of 10 min.
The general method of synthesis is described below, but the specific synthetic method is reported together with 
an example of compound characterization. All compound characterizations can be found in the Supplementary 
information.
Synthesis of the compounds. Solid phase synthesis was carried out on 2-chlorotrityl-N-Fmoc-hydroxylamine 
polymer-bound resin (170 mg, 0.12 mmol, Iris Biotech GmbH). The resin was conditioned for 24 h with dimethyl-
formamide (DMF). Deprotection of the hydroxylamine was performed with a solution of 20% piperidine in DMF 
(3 × 3 mL for 3 min each time) [Sol. A]. Then, the resin was washed with DMF (3 × 3 mL). Furthermore, the 
coupling reaction was carried out with the corresponding N-Fmoc-α amino acid (1, 0.48 mmol, 4 equivalents, GI 
Biochem, Shangai). As the coupling reagent, HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]
pyridinium 3-oxide hexafluorophosphate) or DIC (N,N′-diisopropylcarbodiimide) was used in the presence of 
the additive HOAt (1-hydroxy-7-azabenzotriazole) and DIPEA (diisopropylethylamine); an excess of 4 equiv-
alents of each reagent was used regarding the charge of the resin (0.48 mmol of each compound; Gl Biochem 
Shangai, Iris Biotech GmbH, Sigma-Aldrich, respectively) [Sol. B]. Sol. B was allowed to react at room tempera-
ture with 1 min of preactivation time, and the reaction was carried out for 1 h at room temperature (Scheme 2). 
After this time, the resin was washed three times with three milliliters (3 × 3 mL) of DMF. Deprotection of the 
Fmoc-α-amino acid (3) was performed with Sol. A. Finally, the carboxylic acid (5) was coupled using an excess 
of 4 equivalents and Sol. B (Scheme 2), following the acylation reaction conditions mentioned above.
The final compound (7) was obtained after resin cleavage using 4 mL of 5% trifluoroacetic acid solution (TFA) 
in DCM/triethylsilane (TES) [Sol. C] for 30 min (Scheme 2). Then, the product was recovered by filtration, and 
the resin was washed with 5 mL of Sol. C and DCM (5 × 3 mL). The resulting solution was carefully evaporated to 
dryness in a rotary evaporator. The solid obtained was purified by recrystallization with diethyl ether (previously 
cooled) or using flash chromatography.
General Synthetic Procedure for synthesis of compound N-(2-(hydroxyamino)-2-oxoethyl)benzamide 
(GH38). The procedure was followed starting from 0.12 mmol of resin, HATU (187 mg, 0.49 mmol), HOAt 
(67 mg, 0.49 mmol), DIPEA (86 µL, 0.49 mmol), Fmoc-glycine (146 mg, 0.49 mmol) and benzoic acid (60 mg, 
0.49 mmol). The compound was purified through a flash chromatography using as mobile phase AcOEt/MeOH/
MeCN/H2O (70/2.5/1.25/1.25). A white solid was obtained (0.015 g, 57%). 1H NMR (300 MHz, DMSO-d6) δ 
10.59 (s, 1H, OHacid), 8.80 (s, 1H, NHacid), 8.72 (s, 1H, NHamide), 7.90 (d, J = 7.5 Hz, 2H, H-2, H-6), 7.57–741 
(m, 3H, H-3, H-4, H-5), 3.81 (d, J = 5.5 Hz, 2H, H-1′). 13C NMR (75 MHz, DMSO-d6) δ 166.5 (COacid), 166.0 
(COamide), 134.0 (C-1), 131.3 (C-4), 128.2 (C-3, C-5), 127.4 (C-2, C-6), 40.6 (C-1′). HRMS (ESI): Calculated for 
[C9H10N2O3Na]+ [M + Na]+ 217.0589, found 217.0592. HPLC (Method B, λ: 230 nm): tR 2.51, HPLC purity = 
100%.
General Synthetic Procedure for synthesis of compound N-(2-(hydroxyamino)-2-oxoethyl)-4-methyl ben-
zamide (GH18). The procedure was followed starting from 0.12 mmol of resin, HATU (179 mg, 0.49 mmol), 
HOAt (64 mg, 0.47 mmol), DIPEA (82 µL, 0.47 mmol), Fmoc-glycine (140 mg, 0.47 mmol) and 4-methylbenzoic 
acid (65 mg, 0.47 mmol). The compound was purified through a flash chromatography using as mobile phase 
AcOEt/MeOH/MeCN/H2O (70/2.5/1.25/1.25). A white solid was obtained (0.01 g, 40%). 1H NMR (300 MHz, 
DMSO-d6) δ 8.77 (sa, 1H, NHacid), 8.60 (sa, 1H, NHamide), 7.77 (d, J = 9.0 Hz, 2H, H-2, H-6), 7.27 (d, J = 9.0 Hz, 
2H, H-3, H-5), 3.77 (d, J = 6.0 Hz, 2H, H-1′), 2.35 (s, 3H, H-7). 13C NMR (75 MHz, DMSO-d6) δ 166.3 (COacid), 
166.0 (COamide), 141.1 (C-4), 131.2 (C-1), 128.7 (C-3, C-5), 127.3 (C-2, C-6), 40.4 (C-1′), 20.9 (C-7). HRMS (ESI) 
calculated for [C10H12N2O3]+ [M + Na]+ 231.0746; found 231.0753. HPLC (Method B, λ: 240 nm): tR 3.35, HPLC 
purity = 100%.
General Synthetic Procedure for synthesis of compound 4-butyl-N-(2-(hydroxyamino)-2-oxoethyl)ben-
zamide (GH27). The procedure was followed starting from 0.12 mmol of resin, HATU (184 mg, 0.48 mmol), 
HOAt (66 mg, 0.48 mmol), DIPEA (84 µL, 0.48 mmol), Fmoc-glycine (144 mg, 0.48 mmol) and 4-butylbenzoic 
acid (86 mg, 0.48 mmol). The compound was purified through a flash chromatography using as mobile phase 
AcOEt/MeOH/MeCN/H2O (70/2.5/1.25/1.25). A white solid was obtained (0.008 g, 26%). 1H NMR (300 MHz, 
DMSO-d6): δ 10.57 (sa, 1H, OHacid), 8.78 (sa, 1H, NHacid), 8.62 (sa, 1H, NHamide), 7.80 (d, J = 9.0 Hz, 2H, H-2, 
H-6), 7.29 (d, J = 9.0 Hz, 2H, H-3, H-5), 3.79 (d, J = 6.0 Hz, 2H, H-1′), 2.64 (t, J = 7.5 Hz, 2H, H-7), 1.58 (quintet, 
J = 7.5 Hz, 2H, H-8), 1.30 (m, J = 7.5 Hz, 2H, H-9), 0.91 (t, J = 7.5 Hz, 3H, H-10). 13C NMR (75 MHz, DMSO-d6): 
δ 166.5 (COacid), 166.2 (COamide), 146.1 (C-4), 131.7 (C-1), 128.3 (C-2, C-6), 127.5 (C-3, C-5), 40.7 (C-1′), 34.8 
(C-7), 33.0 (C-8), 21.9 (C-9), 13.9 (C-10). HRMS (ESI): calculated for [C13H18N2O3Na]+ [M + Na]+ 273.1215; 
found 273.1221. HPLC (Method A, λ: 230 nm): tR 3.20, HPLC purity = 100%.
General Synthetic Procedure for synthesis of compound (S)-N-(1-(hydroxyamino)-1-oxo-3-phenylpropan-
2-yl)benzamide (FH38). The procedure was followed starting from 0.12 mmol of resin, HATU (184 mg, 
0.48 mmol), HOAt (66 mg, 0.48 mmol), DIPEA (84 µL, 0.48 mmol), Fmoc-L-Phenylalanine (187 mg, 0.48 mmol) 
and benzoic acid (59 mg, 0.48 mmol). The compound was purified through recrystallization from DCM. A white 
solid was obtained (0.008 g, 23%). 1H NMR (300 MHz, DMSO-d6): δ 10.76 (sa, 1H, OHacid), 8.87 (sa, 1H, NHacid), 
8.59 (d, J = 6.0 Hz, 1H, NHamide), 7.79 (d, J = 7.1 Hz, 2H, H-2, H-6), 7.56–7.08 (m, 8H, H-3, H-4, H-5, H-5′, H-6′, 
H-7′, H-8′, H-9′), 4.60 (dd, J = 8.1, 6.0 Hz, 1H, H-2′), 3.02 (d, J = 6.0 Hz, 2H, H-3′). HRMS (ESI): calculated for 
[C16H16N2O3Na]+ [M + Na]+ 307.1059; found 307.1051. HPLC (Method A, λ: 214 nm): tR 2.51, HPLC purity = 
100%.
General Synthetic Procedure for synthesis of compound (S)-N-(1-(hydroxyamino)-1-oxo-3-phenylpropan-
2-yl)-4-methylbenzamide (FH18).The procedure was followed starting from 0.12 mmol of resin, HATU (184 mg, 
0.48 mmol), HOAt (66 mg, 0.48 mmol), DIPEA (84 µL, 0.48 mmol), Fmoc-L-Phenylalanine (187 mg, 0.48 mmol) 
and 4-methylbenzoic acid (66 mg, 0.48 mmol). The compound was purified through recrystallization from DCM. 
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A beige solid was obtained (0.016 g, 48%). 1H NMR (300 MHz, DMSO-d6): δ 10.75 (sa, 1H, OHacid), 8.86 (sa, 1H, 
NHacid), 8.49 (d, J = 9.0 Hz, 1H, NHamide), 7.71 (d, J = 8.0 Hz, 2H, H-2, H-6), 7.37–7.09 (m, 7H, H-3, H-5, H-5′, 
H-6′, H-7′, H-8′, H-9′), 4.59 (dd, J = 15.0, 9.0 Hz, 1H, H-2′), 3.01 (d, J = 9.0 Hz, 2H, H-3′), 2.33 (s, 3H, H-7). 13C 
NMR (75 MHz, DMSO-d6): δ 168.2 (COacid), 166.0 (COamide), 141.1 (C-4), 138.3 (C-4′), 131.2 (C-1), 129.2 (C-5′, 
C-9′), 128.7 (C-6′, C-8′), 128.1 (C-3, C-5), 127.5 (C-2, C-6), 126.3 (C-7′), 52.7 (C-2′), 37.4 (C-3′), 21.0 (C-7). 
HRMS (ESI): calculated for [C17H19N2O3]+ [M + H]+ 299.1396; found 299.1398. HPLC (Method A, λ: 230 nm): 
tR 9.29, HPLC purity = 100%
General Synthetic Procedure for synthesis of compound (S)−4-butyl-N-(1-(hydroxyamino)-1-oxo-
3-phenylpropan-2-yl)benzamide (FH27).The procedure was followed starting from 0.12 mmol of resin, HATU 
(189 mg, 0.50 mmol), HOAt (68 mg, 0.50 mmol), DIPEA (87 µL, 0.50 mmol), Fmoc-L-Phenylalanine (192 mg, 
0.50 mmol) and 4-butylbenzoic acid (88 mg, 0.50 mmol). The compound was purified through recrystallization 
from DCM. A white solid was obtained (0.028 g, 65%). 1H NMR (300 MHz, DMSO-d6): δ 10.75 (sa, 1H, OHacid), 
8.86 (sa, 1H, NHacid), 8.49 (d, J = 9.0 Hz, 1H, NHamide), 7.72 (d, J = 8.0 Hz, 2H, H-2, H-6), 7.42–7.08 (m, 7H, H-3, 
H-5, H-5′, H-6′, H-7′, H-8′, H-9′), 4.59 (d, J = 6.0 Hz, 1H, H-2′), 3.01 (d, J = 9.0 Hz, 2H, H-3′), 2.61 (t, J = 7.5 Hz, 
2H, H-7), 1.56 (m, 2H, H-8), 1.29 (m, 2H, H-9), 0.89 (t, J = 7.5 Hz, 3H, H-10). 13C NMR (75 MHz, DMSO-d6): δ 
168.6 (COacid), 166.5 (COamide), 146.3 (C-4), 138.7 (C-4′), 131.9 (C-1), 129.6 (C-5′, C-9′), 128.5 (C-6′, C-8′), 128.4 
(C-2, C-6), 127.9 (C-3, C-5), 126.7 (C-7′), 53.1 (C-2′), 37.9 (C-3′), 35.1 (C-7), 33.3 (C-8), 22.1 (C-9), 14.2 (C-10). 
HRMS (ESI): calculated for [C20H25N2O3]+ [M + H]+ 341.1865; found 341.1866. HPLC (Method A, λ: 240 nm): 
tR 9.16. HPLC purity = 100%.
General Synthetic Procedure for synthesis of compound (S)-N-(1-(hydroxyamino)-1-oxo-3-phenylpropan-2-yl)-
2-propylpentanamide (FH37).The procedure was followed starting from 0.12 mmol of resin, HATU (189 mg, 
0.50 mmol), HOAt (68 mg, 0.50 mmol), DIPEA (87 µL, 0.50 mmol), Fmoc-L-Phenylalanine (192 mg, 0.50 mmol) 
and valproic acid (50 µL, 0.50 mmol). The compound was purified through recrystallization from DCM. A white 
solid was obtained (0.013 g, 36%). 1H NMR (300 MHz, DMSO-d6): δ 10.62 (s, 1H, OHacid), 8.84 (s, 1H, NHacid), 
8.03 (d, J = 9.0 Hz, 1H, NHamide), 7.33–7.10 (m, 5H, H-5′, H-6′, H-7′, H-8′, H-9′), 4.46 (m, 1H, H-2′), 2.93–2.68 
(m, 2H, H-3′), 2.15 (m, 1H, H-1), 1.40–0.92 (m, 6H, H-2(2×), H-3), 0.90–0.60 (m, 8H, H-2, H-3(2×)). 13C NMR 
(75 MHz, DMSO-d6): δ 174.4 (COacid), 168.2 (COamide), 137.7 (C-4′), 129.0 (C-5′, C-9′), 127.8 (C-6′, C-8′), 126.0 
(C-7′), 51.2 (C-2′), 44.7 (C-1), 37.9 (C-3′), 34.9 and 34.5 (C-2), 20.0 and 19.6 (C-3), 14.0 and 13.8 (C-4). HRMS 
(ESI): calculated for [C17H27N2O3]+ [M + H]+ 307.2022; found 307.2026. HPLC (Method A, λ: 214 nm): tR 6.37. 
HPLC purity = 100%
General Synthetic Procedure for synthesis of compound (S)-4-butyl-N-(1-(hydroxyamino)-3-(4-hydroxyphenyl)-
1-oxopropan-2-yl)benzamide (YSL99).The procedure was followed starting from 0.14 mmol of resin, HATU 
(216 mg, 0.57 mmol), HOAt (77 mg, 0.57 mmol), DIPEA (99 µL, 0.57 mmol), Fmoc-L-Tyr(tBu)-OH (261 mg, 
0.57 mmol) and 4-butylbenzoic acid (101 mg, 0.57 mmol), and additional step was required once the product 
was cleavage from the resin in order to remove the N-Boc group which is removed with 10% trifluoroacetic 
acid (TFA)/DCM in presence of triethylsilane after 30 min of stirring at room temperature. The compound was 
purified through a flash chromatography using as mobile phase AcOEt/MeOH/MeCN/H2O (70/2.5/1.25/1.25). 
A beige solid was obtained (0.0043 g, 8.5%). 1H NMR (300 MHz, DMSO-d6): δ 10.69 (s, 1H, OHacid), 9.11 (s, 
1H, OHphenol), 8.82 (s, 1H, NHacid), 8.40 (d, J = 6.0 Hz, 1H, NHamide), 7.72 (d, J = 8.1 Hz, 2H, H-2, H-6), 7.24 
(d, J = 8.0 Hz, 2H, H-3, H-5), 7.09 (d, J = 8.4 Hz, 2H, H-5′, H-9′), 6.62 (d, J = 8.3 Hz, 2H, H-6′, H-8′), 4.50 (dd, 
J = 15.0, 6.0 Hz, 1H, H-2′), 2.89 (d, J = 6 Hz, 2H, H-3′), 2.61 (t, J = 7.5 Hz, 2H, H-7), 1.55 (quintet, J = 7.5 Hz, 2H, 
H-8), 1.37–1.27 (m, J = 7.5 Hz, 2H, H-9), 0.89 (t, J = 7.5 Hz, 3H, H-10). 13C NMR (75 MHz, DMSO-d6): δ 168.7 
(COacid), 166.5 (COamide), 156.2 (C-7′), 146.3 (C-4), 132.0 (C-1), 130.5 (C-5′, C-9′), 128.7 (C-4′), 128.4 (C-2, 
C-6), 127.9 (C-3, C-5), 115.3 (C-6′, C-8′), 53.5 (C-2′), 37.1 (C-3′), 35.1 (C-7), 33.3 (C-8), 22.2 (C-9), 14.2 (C-10). 
HRMS (ESI): calculated for [C20H25N2O4]+ [M + H]+ 357.1814; found 357.1814. HPLC (Method A, λ: 230 nm): 
tR 5.29, HPLC purity = 100%.
General Synthetic Procedure for synthesis of compound (R)-4-butyl-N-(1-(hydroxyamino)-1-oxo-
3-phenylpropan-2-yl)benzamide (YSL-106). The procedure was followed starting from 0.14 mmol of resin, DIC 
(57 µ, 0.57 mmol), HOAt (78 mg, 0.57 mmol), Fmoc-D-Phenylalanine (222 mg, 0.57 mmol) and 4-butylbenzoic 
acid (102 mg, 0.57 mmol). The compound was purified through a recrystallization from DCM. A white solid was 
obtained (0.0248 g, 51%). 1H NMR (300 MHz, DMSO-d6): δ 10.76 (s, 1H, OHacid), 8.91 (sa, 1H, NHacid), 8.51 (d, 
J = 9.0 Hz, 1H, NHamide), 7.74 (d, J = 9.0 Hz, 2H, H-2, H-6), 7.43–7.09 (m, 7H, H-3, H-5, H-5′, H-6′, H-7′, H-8′, 
H-9′), 4.61 (dd, J = 13.5, 9 Hz, 1H, H-2′), 3.03 (d, J = 9.0 Hz, 2H, H-3′), 2.62 (t, J = 7.5 Hz, 2H, H-7), 1.57 (quin-
tet, J = 7.5 Hz, 2H, H-8), 1.31 (sextet, J = 7.5 Hz, 2H, H-9), 0.90 (t, J = 7.5 Hz, 3H, H-10). 13C NMR (75 MHz, 
DMSO-d6): δ 171.3 (COacid), 169.2 (COamide), 149.0 (C-4), 141.4 (C-4′), 134.6 (C-1), 132.2 (C-5′, C-9′), 131.2 
(C-6′, C-8′), 131.1 (C-2, C-6), 130.6 (C-3, C-5), 129.4 (C-7′), 55.8 (C-2′), 40.5 (C-3′), 37.7 (C-7), 36.0 (C-8), 
24.8 (C-9), 16.9 (C-10). HRMS (ESI): calculated for [C20H25N2O3]+ [M + H]+ 341.1865; found 341.1860. HPLC 
(Method A, λ: 240 nm): tR 9.23, HPLC purity = 100%.
General Synthetic Procedure for synthesis of compound (S)-4-butyl-N-(1-(hydroxyamino)-3-(naphthalen-
1-yl)-1-oxopropan-2-yl)benzamide (YSL-109). The procedure was followed starting from 0.14 mmol of resin, 
DIC (57 µ, 0.57 mmol), HOAt (78 mg, 0.57 mmol), Fmoc-3-(1-naphtyl)-L-alanine (251 mg, 0.57 mmol) and 
4-butylbenzoic acid (102 mg, 0.57 mmol). The compound was purified through a recrystallization from DCM. 
A white solid was obtained (0.0365 g, 65%). 1H NMR (300 MHz, DMSO-d6): δ 10.88 (s, 1H, OHacid), 8.90 (s, 
1H, NHacid), 8.60 (d, J = 9.0 Hz, 1H, NHamide), 8.29 (d, J = 9.0 Hz, 1H, aromatic), 7.92 (d, J = 9 Hz, 1H, aromatic), 
7.82–7.20 (m, 9H, aromatic), 4.80 (dd, J = 12.0, 6.0 Hz, 1H, H-2′), 3.60 (dd, J = 13.5, 4.5 Hz, 1H, H-3a’), 3.44 
(dd, J = 12.0, 10.5 Hz, 1H, H-3b’), 2.62 (t, J = 7.5 Hz, 2H, H-7), 1.56 (quintet, J = 7.5 Hz, 2H, H-8), 1.30 (sex-
tet, J = 7.5 Hz, 2H, H-9), 0.90 (t, J = 6.0 Hz, 3H, H-10). 13C NMR (75 MHz, DMSO-d6): δ 171.1 (COacid), 
169.2 (COamide), 149.0 (C-4), 137.0 (C-4′), 136.5 (C-aromatic), 134.6 (C-aromatic), 134.5 (C-aromatic), 131.7 
(C-aromatic), 131.1 (C-2, C-6), 130.7 (C-3, C-5), 130.6 (C-aromatic), 130.2 (C-aromatic), 129.3 (C-aromatic), 
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128.7 (C-aromatic), 128.4 (C-aromatic), 126.9 (C-aromatic), 54.9 (C-2′), 37.8 (C-3′), 37.7 (C-7), 36.0 (C-8), 
24.8 (C-9), 16.9 (C-10). HRMS (ESI): calculated for [C24H27N2O3]+ [M + H]+ 391.2022; found 391.2016. HPLC 
(Method A, λ: 214 nm): tR 11.17. HPLC purity = 100%
General Synthetic Procedure for synthesis of compound (S)-4-butyl-N-(1-(hydroxyamino)-3-(naphthalen-
2-yl)-1-oxopropan-2-yl)benzamide (YSL-112). The procedure was followed starting from 0.14 mmol of resin, 
DIC (57 µ, 0.57 mmol), HOAt (78 mg, 0.57 mmol), Fmoc-3-(2-naphtyl)-L-alanine (251 mg, 0.57 mmol) and 
4-butylbenzoic acid (102 mg, 0.57 mmol). The compound was purified through a recrystallization from DCM. 
A white solid was obtained (0.0390 g, 70%). 1H NMR (300 MHz, DMSO-d6): δ 10.79 (s, 1H, OHacid), 8.90 (sa, 
1H, NHacid), 8.58 (d, J = 9.0 Hz, 1H, NHamide), 7.90–7.76 (m, 4H, H-naphtyl), 7.74 (d, J = 9.0 Hz, 2H, H-3, H-5), 
7.60–7.40 (m, 3H, H- naphtyl), 7.25 (d, J = 9.0 Hz, 2H, H-3, H-5), 4.73 (dd, J = 15.0, 9.0 Hz, 1H, H-2′), 3.21 (d, 
J = 6.0 Hz, 2H, H-3′), 2.61 (t, J = 9.0 Hz, 2H, H-7), 1.55 (quintet, J = 7.5 Hz, 2H, H-8), 1.30 (sextet, J = 7.5 Hz, 
2H, H-9), 0.89 (t, J = 7.5 Hz, 3H, H-10). 13C NMR (75 MHz, DMSO-d6): δ 171.2 (COacid), 169.2 (COamide), 149.0 
(C-4), 139.1 (C-4′), 136.0 (C-1), 134.9 (C-naphthyl), 134.6 (C-naphthyl), 131.1 (C-2, C-6), 130.9 (C-3, C-5), 130.6 
(C-naphthyl), 130.5 (C-naphthyl), 130.4 (C-naphthyl), 129.1 (C-naphthyl), 128.5 (C-naphthyl), 55.8 (C-2′), 40.7 
(C-3′), 37.7 (C-7), 36.0 (C-8), 24.8 (C-9), 16.9 (C-10). HRMS (ESI): calculated for [C24H27N2O3]+ [M + H]+ 
391.2022; found 391.2030. HPLC (Method A, λ: 230 nm): tR 11.10. HPLC purity = 100%.
General Synthetic Procedure for synthesis of compound (S)-4-butyl-N-(3-(4-fluorophenyl)-1-
(hydroxyamino)-1-oxopropan-2-yl)benzamide (YSL-116). The procedure was followed starting from 0.14 mmol 
of resin, DIC (57 µ, 0.57 mmol), HOAt (78 mg, 0.57 mmol), Fmoc-L-Phe(4-F)-OH (232 mg, 0.57 mmol) and 
4-butylbenzoic acid (102 mg, 0.57 mmol). The compound was purified through a flash chromatography using as 
mobile phase AcOEt/MeOH/MeCN/H2O (70/2.5/1.25/1.25). A salmon color solid was obtained (0.102 g, 43%). 
1H NMR (300 MHz, DMSO-d6): δ 10.76 (s, 1H, OHacid), 8.89 (s, 1H, NHacid), 8.52 (d, J = 8.6 Hz, 1H, NHamide), 
7.74 (d, J = 8.0 Hz, 2H, H-2, H-6), 7.36 (dd, J = 8.0 Hz, 4JH-F = 6.0 Hz, 2H, H-5′, H-9′), 7.26 (d, J = 7.9 Hz, 2H, H-3, 
H-5), 7.09 (dd, J = 8.8 Hz, 3JH-F = 8.8 Hz, 2H, H-6′, H-8′), 4.58 (dd, J = 15.3, 7.9 Hz, 1H, H-2′), 3.02 (d, J = 7.2 Hz, 
2H, H-3′), 2.63 (t, J = 7.6 Hz, 2H, H-7), 1.57 (quintet, J = 7.6 Hz, 2H, H-8), 1.31 (sextet, J = 7.2 Hz, 2H, H-9), 
0.90 (t, J = 7.3 Hz, 3H, H-10). 13C NMR (75 MHz, DMSO-d6): δ 168.5 (COacid), 166.6 (COamide), 161.4 (C-7′, 
1JC-F = 144 Hz), 146.4 (C-4), 134.9 (C-1), 131.9 (C-4′), 131.4 (C-5′, C-9′, 3JC-F = 5.3 Hz), 128.5 (C-2, C-6), 128.0 
(C-3, C-5), 115.3 (C-6′, C-8′, 2JC-F = 12.8 Hz), 53.2 (C-2′), 37.0 (C-3′), 35.1 (C-7), 33.4 (C-8), 22.2 (C-9), 14.2 
(C-10). HRMS (ESI): calculated for [C20H24N2O3F]+ [M + H]+ 359.1771; found 359.1773. HPLC (Method A, λ: 
240 nm): tR 9.48. HPLC purity = 100%.
General Synthetic Procedure for synthesis of compound (S)-4-butyl-N-(1-(hydroxyamino)-3-(4-iodophenyl)-
1-oxopropan-2-yl)benzamide (YSL-121). The procedure was followed starting from 0.14 mmol of resin, DIC 
(57 µ, 0.57 mmol), HOAt (78 mg, 0.57 mmol), Fmoc-L-Phe(4-I)-OH (294 mg, 0.57 mmol) and 4-butylbenzoic 
acid (102 mg, 0.57 mmol). The compound was purified through a recrystallization from DCM. A white solid 
was obtained (0.044 g, 66%). 1H NMR (300 MHz, DMSO-d6): δ 10.76 (s, 1H, OHacid), 8.88 (s, 1H, NHacid), 8.52 
(d, J = 9.0 Hz, 1H, NHamide), 7.74 (d, J = 9.0 Hz, 2H), 7.63 (d, J = 9.0 Hz, 2H), 7.27 (d, J = 9.0 Hz, 2H), 7.15 (d, 
J = 9.0 Hz, 2H), 4.58 (dd, J = 15.0, 9.0 Hz, 1H, H-2′), 2.98 (d, J = 6.0 Hz, 2H, H-3′), 2.63 (t, J = 7.5 Hz, 2H, H-7), 
1.57 (quintet, J = 7.5 Hz, 2H, H-8), 1.31 (sextet, J = 7.5 Hz, 2H, H-9), 0.91 (t, J = 7.5 Hz, 3H, H-10). 13C NMR 
(75 MHz, DMSO-d6): δ 171.0 (COacid), 169.2 (COamide), 149.1 (C-4), 141.2 (C-6′, C-8′), 139.9 (C-4′), 134.7 (C-1), 
134.5 (C-5′, C-9′), 131.1 (C-2, C-6), 130.6 (C-3, C-5), 95.4 (C-7′), 55.6 (C-2′), 40.0 (C-3′), 37.7 (C-7), 36.0 (C-8), 
24.8 (C-9), 16.9 (C-10). HRMS (ESI): calculated for [C20H24N2O3I]+ [M + H]+ 467.0832; found 467.0838. HPLC 
(Method A, λ: 230 nm): tR 11.28. HPLC purity = 100%.
General Synthetic Procedure for synthesis of compound (S)-4-butyl-N-(1-(hydroxyamino)-3-(4-nitrophenyl)-
1-oxopropan-2-yl)benzamide (YSL-125). The procedure was followed starting from 0.14 mmol of resin, DIC 
(57 µ, 0.57 mmol), HOAt (78 mg, 0.57 mmol), Fmoc-L-Phe(4-NO2)-OH (248 mg, 0.57 mmol) and 4-butylbenzoic 
acid (102 mg, 0.57 mmol). The compound was purified through a flash chromatography using as mobile phase 
AcOEt/MeOH/MeCN/H2O (70/2.5/1.25/1.25). A white solid was obtained (0.03 g, 60%). 1H NMR (300 MHz, 
DMSO-d6): δ 8.61 (d, J = 9.0 Hz, 1H, NHamide), 8.15 (d, J = 9.0 Hz, 2H, H-6′, H-8′), 7.72 (d, J = 6.0 Hz, 2H, H-2, 
H-6), 7.60 (d, J = 9.0 Hz, 2H, H-5′, H-9′), 7.25 (d, J = 6.0 Hz, 2H, H-3, H-5), 4.67 (ddd, J = 9.0, 9.0, 6.0 Hz, 1H, 
H-2′), 3.18 (dd, J = 6.0, 3.0 Hz, 1H, H-3′), 2.61 (t, J = 9.0 Hz, 2H, H-7), 1.54 (m, J = 9.0 Hz, 2H, H-8), 1.29 (sex-
tet, J = 9.0 Hz, 2H, H-9), 0.89 (t, J = 6.0 Hz, 3H, H-10).13C NMR (75 MHz, DMSO-d6): δ 170.7 (COacid), 169.2 
(COamide), 149.8 (C-7′), 149.3 (C-4′), 149.1 (C-4), 134.4 (C-1), 133.6 (C-5′, C-9′), 131.2 (C-2, C-6), 130.6 (C-3, 
C-5), 126.3 (C-6′, C-8′), 55.3 (C-2′), 40.3 (C-3′), 37.7 (C-7), 36.0 (C-8), 24.8 (C-9), 16.9 (C-10). HRMS (ESI): 
calculated for [C20H24N3O5]+ [M + H]+ 386.1716; found 386.1714. HPLC (Method A, λ: 254 nm): tR 9.34. HPLC 
purity = 100%.
General Synthetic Procedure for synthesis of compound (S)-4-butyl-N-(2-(hydroxyamino)-2-oxo-
1-phenylethyl) benzamide (YSL-129). The procedure was followed starting from 0.14 mmol of resin, DIC (57 µ, 
0.57 mmol), HOAt (78 mg, 0.57 mmol), Fmoc-Phg-OH (214 mg, 0.57 mmol) and 4-butylbenzoic acid (102 mg, 
0.57 mmol). The compound was purified through a recrystallization from DCM. A white solid was obtained 
(0.004 g, 8.6%). 1H NMR (300 MHz, DMSO-d6): δ 11.02 (sa, 1H, OHacid), 8.98 (s, 1H, NHacid), 8.72 (d, J = 9.0 Hz, 
1H, NHamide), 7.83 (d, J = 6.0 Hz, 2H, H-2, H-6), 7.50 (d, J = 6.0 Hz, 2H, H-3, H-5), 7.40–719 (m, 5H, H-5′, H-6′, 
H-7′, H-8′, H-9′), 5.60 (d, J = 6.0 Hz, 1H, H-1′), 2.62 (t, J = 7.5 Hz, 2H, H-7), 1.56 (quintet, J = 7.5 Hz, 2H, H-8), 
1.30 (sextet, J = 7.5 Hz, 2H, H-9), 0.89 (t, J = 7.5 Hz, 3H, H-10). 13C NMR (75 MHz, DMSO-d6): δ 169.8 (COacid), 
169.2 (COamide), 149.2 (C-4), 141.6 (C-3′), 134.4 (C-1), 131.3 (C-5′, C-7′), 131.2 (C-2, C-6), 130.9 (C-3, C-5), 
130.7 (C-4′, C-8′), 130.5 (C-6′), 57.7 (C-2′), 37.7 (C-7), 36.0 (C-8), 24.8 (C-9), 16.9 (C-10). HRMS (ESI): calcu-
lated for [C19H23N2O3]+ [M + H]+ 327.1709; found 327.1707. HPLC (Method A, λ: 240 nm): tR 9.11. HPLC purity 
= 100%.
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Biological evaluation. Cytotoxicity test. A colorimetric assay using MTT was used to monitor cell survival 
and to determine the 50% inhibitory concentration (IC50)44. All compounds were evaluated in triplicate using six 
points, 1/3 dilutions, with the highest concentration of 50 µM. The triplicate measurements were placed in three 
different 96-plates, and 1% DMSO was used as a negative control.
The first sets of 8 compounds (GH38, GH18, GH27, FH38, FH18, FH27 and FH37) were evaluated in dif-
ferent cancer cell lines: HepG2, MCF-7, SH-SY5Y, MIA PaCa-2, and FH27. Furthermore, the second series of 
eight compounds were evaluated using seven cell lines: SH-SY5Y which is a neuroblastoma cell line; HepG2, a 
hepatocellular carcinoma cell line; MIA PaCa-2, a human pancreatic carcinoma cell line; MCF-7, a breast cancer 
cell line; HCC1954, a basal-Her2+ breast carcinoma cell line; RCC4-VA, a renal carcinoma cell line with a VHL 
mutation; and RCC4-VHL, a renal carcinoma cell without the VHL mutation (wild type). The cells used were 
seeded in 96-well plates and left for 24 h (5% CO2 and 90% humidity, 50000 cells/well) and incubated for 3 days 
to study the cytotoxicity.
Enzymatic inhibition assay. HDAC1 (BML-AK511), HDAC6 (BML-AK516) and HDAC8 (BML-AK518) 
activity was determined using a commercial assay kit from Enzo Life Sciences (HDAC fluorometric assay/drug 
discovery kit, Farmingdale, NY, USA). The assay was carried out according to the manufacturer’s instructions. 
Fluorescence intensity was measured at an excitation wavelength of 360 nm and an emission wavelength of 
460 nm using a fluorometer (LS 55, Perkin Elmer, USA). Trichostatin A (TSA) was also evaluated as a positive 
control. IC50 values were determined using GraphPad Prism 5 software.
Statistical analysis. ANOVA test was performed use to determine any significant difference between each 
compound treatment and the DMSO control Statistical test and EC50 and IC50 calculations were performed using 
GraphPad Prism.
Received: 30 January 2020; Accepted: 2 June 2020;
Published: xx xx xxxx
References
 1. Glozak, M. A., Sengupta, N., Zhang, X. & Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15–23, https://
doi.org/10.1016/j.gene.2005.09.010 (2005).
 2. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S. & van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization 
of the classical HDAC family. Biochem J 370, 737–749, https://doi.org/10.1042/BJ20021321 (2003).
 3. Legube, G. & Trouche, D. Regulating histone acetyltransferases and deacetylases. EMBO reports 4, 944–947, https://doi.org/10.1038/
sj.embor.embor941 (2003).
 4. Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1, 194–202, https://doi.org/10.1038/35106079 
(2001).
 5. Dickinson, M., Johnstone, R. W. & Prince, H. M. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer 
effect. Invest New Drugs 28(Suppl 1), S3–20, https://doi.org/10.1007/s10637-010-9596-y (2010).
 6. Kim, H. J. & S.C., B. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J 
Transl Res 3, 166–179 (2011).
 7. Butler, K. V. et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. Journal of 
the American Chemical Society 132, 10842–10846, https://doi.org/10.1021/ja102758v (2010).
 8. Dietz, K. C. & Casaccia, P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacological 
research 62, 11–17, https://doi.org/10.1016/j.phrs.2010.01.011 (2010).
 9. McKinsey, T. A. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol 52, 303–319, https://doi.
org/10.1146/annurev-pharmtox-010611-134712 (2012).
 10. Khan, A. N. & Tomasi, T. B. Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res 40, 164–178, 
https://doi.org/10.1007/s12026-007-0085-0 (2008).
 11. Shuttleworth, S. J., Bailey, S. G. & Townsend, P. A. Histone Deacetylase inhibitors: new promise in the treatment of immune and 
inflammatory diseases. Current drug targets 11, 1430–1438, https://doi.org/10.2174/1389450111009011430 (2010).
 12. Brilli, L. L., Swanhart, L. M., de Caestecker, M. P. & Hukriede, N. A. HDAC inhibitors in kidney development and disease. Pediatr 
Nephrol 28, 1909–1921, https://doi.org/10.1007/s00467-012-2320-8 (2013).
 13. Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P. & Gilkeson, G. S. Histone deacetylase inhibitors modulate renal disease in the MRL-
lpr/lpr mouse. J Clin Invest 111, 539–552, https://doi.org/10.1172/JCI16153 (2003).
 14. Luo, R. X. & Dean, D. C. Chromatin Remodeling and Transcriptional Regulation. JNCI. Journal of the National Cancer Institute 91, 
1288–1294, https://doi.org/10.1093/jnci/91.15.1288 (1999).
 15. Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature 
reviews. Cancer 6, 38–51, https://doi.org/10.1038/nrc1779 (2006).
 16. Xu, Y., Zhang, P. & Liu, Y. Chidamide tablets: HDAC inhibition to treat lymphoma. Drugs of today 53, 167–176, https://doi.
org/10.1358/dot.2017.53.3.2595452 (2017).
 17. Batchu, S. N., Brijmohan, A. S. & Advani, A. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clinical 
science 130, 987–1003, https://doi.org/10.1042/CS20160084 (2016).
 18. Khochbin, S., Verdel, A., Lemercier, C. & Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Current 
Opinion in Genetics & Development 11, 162–166, https://doi.org/10.1016/s0959-437x(00)00174-x (2001).
 19. Witt, O., Deubzer, H. E., Milde, T. & Oehme, I. HDAC family: What are the cancer relevant targets? Cancer letters 277, 8–21, https://
doi.org/10.1016/j.canlet.2008.08.016 (2009).
 20. Simoes-Pires, C. et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol 
Neurodegener 8, 7, https://doi.org/10.1186/1750-1326-8-7 (2013).
 21. Li, G., Jiang, H., Chang, M., Xie, H. & Hu, L. HDAC6 alpha-tubulin deacetylase: a potential therapeutic target in neurodegenerative 
diseases. J Neurol Sci 304, 1–8, https://doi.org/10.1016/j.jns.2011.02.017 (2011).
 22. Estiu, G. et al. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. Journal of medicinal chemistry 51, 
2898–2906, https://doi.org/10.1021/jm7015254 (2008).
 23. Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: 
implications for disease and therapy. Nature reviews. Genetics 10, 32–42, https://doi.org/10.1038/nrg2485 (2009).
 24. Furumai, R. et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including 
trapoxin. Proceedings of the National Academy of Sciences 98, 87–92, doi:10.1073/pnas.98.1.87 (2001).
1 6Scientific RepoRtS |        (2020) 10:10462  | https://doi.org/10.1038/s41598-020-67112-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 25. Wang, D. F., Helquist, P., Wiech, N. L. & Wiest, O. Toward selective histone deacetylase inhibitor design: homology modeling, 
docking studies, and molecular dynamics simulations of human class I histone deacetylases. Journal of medicinal chemistry 48, 
6936–6947, https://doi.org/10.1021/jm0505011 (2005).
 26. Wang, D. Computational Studies on the Histone Deacetylases and the Design of Selective Histone Deacetylase Inhibitors. Current 
Topics in Medicinal Chemistry 9, 241–256, https://doi.org/10.2174/156802609788085287 (2009).
 27. Estiu, G. et al. On the inhibition of histone deacetylase 8. Bioorganic & medicinal chemistry 18, 4103–4110, https://doi.org/10.1016/j.
bmc.2010.03.080 (2010).
 28. Dowling, D. P., Gantt, S. L., Gattis, S. G., Fierke, C. A. & Christianson, D. W. Structural studies of human histone deacetylase 8 and 
its site-specific variants complexed with substrate and inhibitors. Biochemistry 47, 13554–13563, https://doi.org/10.1021/bi801610c 
(2008).
 29. Somoza, J. R. et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12, 
1325–1334, https://doi.org/10.1016/j.str.2004.04.012 (2004).
 30. Moradei, O. M. et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. 
Journal of medicinal chemistry 50, 5543–5546, https://doi.org/10.1021/jm701079h (2007).
 31. Bermudez-Lugo, J. A. et al. Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular 
dynamic simulations. Journal of molecular modeling 18, 2301–2310, https://doi.org/10.1007/s00894-011-1240-z (2012).
 32. Sixto-Lopez, Y., Gomez-Vidal, J. A. & Correa-Basurto, J. Exploring the Potential binding Sites of Some Known HDAC Inhibitors on 
Some HDAC8 Conformers by Docking Studies. Applied biochemistry and biotechnology 173, 1907–1926, https://doi.org/10.1007/
s12010-014-0976-1 (2014).
 33. Micelli, C. & Rastelli, G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug discovery today 20, 718–735, 
https://doi.org/10.1016/j.drudis.2015.01.007 (2015).
 34. Wambua, M. K., Nalawansha, D. A., Negmeldin, A. T. & Pflum, M. K. Mutagenesis studies of the 14 A internal cavity of histone 
deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design. Journal of medicinal chemistry 57, 
642–650, https://doi.org/10.1021/jm401837e (2014).
 35. Charrier, C. et al. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene 
expression. Journal of medicinal chemistry 52, 3112–3115, https://doi.org/10.1021/jm9002439 (2009).
 36. Kozikowski, A. P., Tapadar, S., Luchini, D. N., Kim, K. H. & Billadeau, D. D. Use of the nitrile oxide cycloaddition (NOC) reaction 
for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity 
at HDAC6. Journal of medicinal chemistry 51, 4370–4373, https://doi.org/10.1021/jm8002894 (2008).
 37. Sixto-Lopez, Y. et al. Searching the conformational complexity and binding properties of HDAC6 through docking and molecular 
dynamic simulations. Journal of biomolecular structure & dynamics 35, 2794–2814, https://doi.org/10.1080/07391102.2016.123108
4 (2017).
 38. Marks, P. A. & Dokmanovic, M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin 
Investig Drugs 14, 1497–1511, https://doi.org/10.1517/13543784.14.12.1497 (2005).
 39. Rivieccio, M. A. et al. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proceedings of the 
National Academy of Sciences of the United States of America 106, 19599–19604, https://doi.org/10.1073/pnas.0907935106 (2009).
 40. Kong, Y. et al. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Molecular cancer therapeutics 10, 
1591–1599, https://doi.org/10.1158/1535-7163.MCT-10-0779 (2011).
 41. Hai, Y. & Christianson, D. W. Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nature chemical biology 
12, 741–747, https://doi.org/10.1038/nchembio.2134 (2016).
 42. Kumar, G. R., Sangeetha, S., Ranjitha, S. & Murugan, K. Breast Cancer Specific Histone Deacetylase Inhibitors and Lead Discovery 
using Molecular Docking and Descriptor Study. Trends in Bioinformatics 6, 25–44, https://doi.org/10.3923/tb.2013.25.44 (2013).
 43. Narita, K. et al. Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5”-epi-spiruchostatin B, 
FK228 (FR901228) and preliminary evaluation of their biological activity. Chemistry 15, 11174–11186, https://doi.org/10.1002/
chem.200901552 (2009).
 44. Butler, K. V. et al. Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups. ChemMedChem 4, 1292–1301, 
https://doi.org/10.1002/cmdc.200900088 (2009).
 45. Giaccia, A., Siim, B. G. & Johnson, R. S. HIF-1 as a target for drug development. Nature reviews. Drug discovery 2, 803–811, https://
doi.org/10.1038/nrd1199 (2003).
 46. Cautain, B. et al. Identification of the Lipodepsipeptide MDN-0066, a Novel Inhibitor of VHL/HIF Pathway Produced by a New 
Pseudomonas Species. PloS one 10, e0125221, https://doi.org/10.1371/journal.pone.0125221 (2015).
 47. Chen, S. & Sang, N. Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. Journal of 
biomedicine & biotechnology 2011, 197946, https://doi.org/10.1155/2011/197946 (2011).
 48. Kong, X. et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-
inducible factor 1alpha. Molecular and cellular biology 26, 2019–2028, https://doi.org/10.1128/MCB.26.6.2019-2028.2006 (2006).
 49. Qian, D. Z. et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. 
Cancer research 66, 8814–8821, https://doi.org/10.1158/0008-5472.CAN-05-4598 (2006).
 50. Gryder, B. E., Sodji, Q. H. & Oyelere, A. K. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. 
Future medicinal chemistry 4, 505–524, https://doi.org/10.4155/fmc.12.3 (2012).
 51. Santos-Martins, D., Forli, S., Ramos, M. J. & Olson, A. J. AutoDock4(Zn): an improved AutoDock force field for small-molecule 
docking to zinc metalloproteins. Journal of chemical information and modeling 54, 2371–2379, https://doi.org/10.1021/ci500209e 
(2014).
 52. Sixto-López, Y., Bello, M. & Correa-Basurto, J. Insights into structural features of HDAC1 and its selectivity inhibition elucidated by 
Molecular dynamic simulation and Molecular Docking. Journal of Biomolecular Structure and Dynamics, 1–64, https://doi.org/10.1
080/07391102.2018.1441072 (2018).
 53. Zhang, L., Zhang, J., Jiang, Q., Zhang, L. & Song, W. Zinc binding groups for histone deacetylase inhibitors. J Enzyme Inhib Med 
Chem 33, 714–721, https://doi.org/10.1080/14756366.2017.1417274 (2018).
 54. Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234, 779–815, https://doi.
org/10.1006/jmbi.1993.1626 (1993).
 55. Seto, E. & Yoshida, M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol 6, a018713, 
https://doi.org/10.1101/cshperspect.a018713 (2014).
 56. Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational 
chemistry 30, 2785–2791, https://doi.org/10.1002/jcc.21256 (2009).
 57. Case, D. A. et al. The Amber biomolecular simulation programs. Journal of computational chemistry 26, 1668–1688, https://doi.
org/10.1002/jcc.20290 (2005).
 58. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. Journal of 
computational chemistry 25, 1157–1174, https://doi.org/10.1002/jcc.20035 (2004).
 59. Hornak, V. et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 
65, 712–725, https://doi.org/10.1002/prot.21123 (2006).
 60. Maier, J. A. et al. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. Journal of chemical 
theory and computation 11, 3696–3713, https://doi.org/10.1021/acs.jctc.5b00255 (2015).
17Scientific RepoRtS |        (2020) 10:10462  | https://doi.org/10.1038/s41598-020-67112-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 61. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for 
simulating liquid water. The Journal of Chemical Physics 79, 926, https://doi.org/10.1063/1.445869 (1983).
 62. Gotz, A. W. et al. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born. Journal of 
chemical theory and computation 8, 1542–1555, https://doi.org/10.1021/ct200909j (2012).
 63. Salomon-Ferrer, R., Gotz, A. W., Poole, D., Le Grand, S. & Walker, R. C. Routine Microsecond Molecular Dynamics Simulations 
with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. Journal of chemical theory and computation 9, 3878–3888, https://
doi.org/10.1021/ct400314y (2013).
 64. Pang, Y.-P. Novel Zinc Protein Molecular Dynamics Simulations: Steps Toward Antiangiogenesis for Cancer Treatment. Journal of 
molecular modeling 5, 196–202, https://doi.org/10.1007/s008940050119 (1999).
 65. Pang, Y. P. X. K., Yazal, J. E. & Prendergas, F. G. Successful molecular dynamics simulation of the zinc-bound farnesyltransferase 
using the cationic dummy atom approach. Protein Science 9, 1857–1865 (2000).
 66. van Gunsteren, W. F. & Berendsen, H. J. C. Algorithms for macromolecular dynamics and constraint dynamics. Molecular Physics 
34, 1311–1327, https://doi.org/10.1080/00268977700102571 (1977).
 67. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. The. Journal of 
Chemical Physics 98, 10089, https://doi.org/10.1063/1.464397 (1993).
 68. Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A. & Haak, J. R. Molecular dynamics with coupling to an external 
bath. The Journal of Chemical Physics 81, 3684, https://doi.org/10.1063/1.448118 (1984).
 69. Gohlke, H. & Case, D. A. Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf. 
Journal of computational chemistry 25, 238–250, https://doi.org/10.1002/jcc.10379 (2004).
 70. Miller, B. R. 3rd et al. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. Journal of chemical theory and 
computation 8, 3314–3321, https://doi.org/10.1021/ct300418h (2012).
 71. Onufriev, A., Bashford, D. & Case, D. A. Exploring protein native states and large-scale conformational changes with a modified 
generalized born model. Proteins 55, 383–394, https://doi.org/10.1002/prot.20033 (2004).
 72. Genheden, S. & Ryde, U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert opinion on drug 
discovery 10, 449–461, https://doi.org/10.1517/17460441.2015.1032936 (2015).
Acknowledgements
We gratefully acknowledge to CONACYT (Grants: CB-254600 and SEP-CONACYT-ANUIES-ECOS Francia: 
296636), to Instituto Politécnico Nacional (Grant: Proyectos Insignia IPN-2015), and to COFAA-SIP/IPN. YSL 
thanks to CONACYT by Ph.D scholarship.
Author contributions
Y.S.L.: Carried out theoretical studies, result analysis and write the article; J.A.V.: Synthesis of compounds; N.D.P.: 
Biological evaluations on cell culture, M.C.R.H.: Kinetic assays on H.D.A.C. using kits; M.B.: Theoretical studies, 
molecular dynamics simulations; J.C.B.: project design, result analysis and write the article.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-67112-4.
Correspondence and requests for materials should be addressed to J.C.-B.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
